Thomas Nelius

Texas Tech University Health Sciences CenterUnited States of America

Thomas Nelius was born in Aschersleben, Germany, in 1967. He received the Medical Degree and Doctor of Philosophy from the University Halle/Wittenberg, Germany in 1994 and 1995, respectively. He completed his Residency in Urology at a Teaching Hospital of the Otto-von-Guericke University Magdeburg, Germany and at the Princess of Wales Hospital, Bridgend, United Kingdom from 1994-2000. He is Board Certified by the German Board of Urology. From 2001-2003, he was a Research Associate of the Department of Urology at Northwestern University Chicago, IL, USA, where he worked on the development of new anti-angiogenic treatment strategies. Presently, he is an Associate Professor in the Department of Urology at Texas Tech University Health Sciences Center, Lubbock, TX, USA. His area of expertise includes also treatment of urological malignancies. He is mainly interested in new treatment strategies for prostate cancer, including e.g. anti-angiogenic strategies and metronomic chemotherapy in patients with hormone-refractory prostate cancer. He is an active reviewer for multiple Medical Journals and and member of the American Urological Association, German Society of Urology, South Central Section of the American Urological Association, American Society of Clinical Oncology, American Association of Cancer Research and Southwest Oncology Group Affiliate Program.

1books edited

2chapters authored

Latest work with IntechOpen by Thomas Nelius

Urinary tract infections (UTI) continue to be under the most common bacterial infections worldwide. Diagnostic and treatment have substantial financial burden on society. In the USA, UTIs are responsible for more than 7 million physician visits annually and about 15% of all community-prescribed antibiotics in the USA are dispensed for UTIs. About 50% of women will experience at least one UTI episode during lifetime, about 1 million emergency department visits due to UTI in the USA alone, resulting in more than 100 000 hospital admissions annually, most often for pyelonephritis. Moreover, UTIs are also the leading cause of hospital-acquired infections, accounting for approximately 40% of all such cases. The majority of these cases are catheter-associated. Therefore, nosocomial UTIs comprise perhaps the largest institutional reservoir for nosocomial antibiotic-resistant pathogens. Beside the economic impact, UTIs affect also significantly the quality of life of the affected population. The aim of this book is to highlight problematic aspects and recent advances in the field of UTIs. The book is divided in three parts.

Go to the book